Many patients with secondary progressive multiple sclerosis (SPMS) are actually being misclassified and treated as if they have relapsing-remitting MS (RRMS), which can have an impact on research, treatment, and health care planning, said Jan Hillert, MD, PhD, professor and senior physician at Karolinska Institutet.
Many patients with secondary progressive multiple sclerosis (SPMS) are actually being misclassified and treated as if they have relapsing-remitting MS (RRMS), which can have an impact on research, treatment, and health care planning, said Jan Hillert, MD, PhD, professor and senior physician at Karolinska Institutet.
Why do you think misclassification of relapsing-remitting MS as secondary progressive MS occurs? And how can that misclassification be avoided?
So, the background is that we've seen that the proportion of people supposedly having SPMS varies between different data sources, whether different materials from different countries different MS registries. And of course, we wonder why that is. Is that because patients with SPMS are neglected by MS care? The reason [is] because they are, they may actually be, misclassified.
And therefore, now that we are starting to get to treatments that are specifically approved for SPMS it becomes more important for us to know: what is the proportion these days of SPMS? And I mean, this is important for us, as physicians to plan our treatments to plan our health care, plan economically, possibly, depending on your system. So, it became really important to know.
And that's why we thought that an objective algorithm that would designate patients into RRMS or SPMS would be a useful thing, at least in research, and also in health care planning, Potentially, also in the clinical situation, depending on how you can use it.
What is the algorithm and how can providers and clinicians use it to make sure that they're not misclassifying patients with MS?
So, the idea though, and there have been several different ways of trying to find the best way to assign RRMS and SPMS. But a general problem with those is that they require quite a bit of information, most typically several points of EDSS [Expanded Disability Status Scale] measurement. Whereas in practical life, as well as in many databases, you have the scarcity of EDSS points.
So, we wanted to set up something simple that required just age and 1 EDSS. And if we could find out an algorithm that could actually do a good job based only on those 2 variables, then that would be great. And that's what we set out to do.
And that, in the end, appeared to be possible. We applied some machine learning techniques to categorize patients into age groups and EDSS groups. And then we came up with the best model, we prune the model to bring it down to something more practical, and then that ended up in this algorithm that we now have as this decision tree classification. And it's not yet published, I should say it's submitted, like to be published pretty soon.
Balancing Cost and Quality in Oncology: A Value-Based Care Perspective
January 30th 2025Travis Brewer, vice president of payer and public health strategy/relations at Texas Oncology, shared that value-based oncology care can achieve both cost efficiency and high-quality outcomes through integrated multidisciplinary teams, flexible payment models, and targeted treatment approaches.
Read More
How FcRn Blockade Targets Myasthenia Gravis Autoantibodies
January 29th 2025In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.
Read More
Unlocking Access: Exploring Mental Health Care Among Medicaid Managed Care Enrollees
January 23rd 2025On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.
Listen
An Argument for Outpatient Bispecific Antibody Delivery: Dr Kirollos Hanna
January 25th 2025Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.
Read More